Cargando…
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
OBJECTIVE: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: Sustained clinical remission was defined as Disease A...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791469/ https://www.ncbi.nlm.nih.gov/pubmed/36549857 http://dx.doi.org/10.1136/rmdopen-2022-002796 |
_version_ | 1784859413297758208 |
---|---|
author | Terslev, L Ostergaard, Mikkel Georgiadis, Stylianos Brahe, Cecilie Heegaard Ellegaard, Karen Dohn, UM Fana, Viktoria Møller, Torsten Juul, Lars Huynh, Tuan Khai Krabbe, Simon Ornbjerg, L M Glinatsi, Daniel Røgind, Henrik Hansen, Annette Nørregaard, Jesper Jacobsen, Søren Jensen, Dorte V Manilo, Natalia Asmussen, Karsten Boesen, Mikael Rastiemadabadi, Zoreh Morsel-Carlsen, Lone Møller, Jakob Møllenbach Krogh, Niels Steen Hetland, Merete Lund |
author_facet | Terslev, L Ostergaard, Mikkel Georgiadis, Stylianos Brahe, Cecilie Heegaard Ellegaard, Karen Dohn, UM Fana, Viktoria Møller, Torsten Juul, Lars Huynh, Tuan Khai Krabbe, Simon Ornbjerg, L M Glinatsi, Daniel Røgind, Henrik Hansen, Annette Nørregaard, Jesper Jacobsen, Søren Jensen, Dorte V Manilo, Natalia Asmussen, Karsten Boesen, Mikael Rastiemadabadi, Zoreh Morsel-Carlsen, Lone Møller, Jakob Møllenbach Krogh, Niels Steen Hetland, Merete Lund |
author_sort | Terslev, L |
collection | PubMed |
description | OBJECTIVE: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year. bDMARDs were tapered according to a mandatory clinical guideline to two-thirds of standard dose at baseline, half of dose at week 16 and discontinuation at week 32. Prospective assessments for 2 years included clinical evaluation, conventional radiography, ultrasound and MRI for signs of inflammation and bone changes. Flare was defined as DAS28-CRP ≥2.6 with ∆DAS28-CRP ≥1.2 from baseline. Baseline predictors of flare were assessed by logistic regression analyses. RESULTS: Of 142 included patients, 121 (85%) flared during follow-up of which 86% regained remission within 24 weeks after flare. Patients that flared were more often rheumatoid factor positive, had tried more bDMARDs and had higher baseline ultrasound synovitis sum scores than those not flaring. For patients on standard dose, predictors of flare within 16 weeks after reduction to two-thirds of standard dose were baseline MRI-osteitis (OR 1.16; 95% CI 1.03 to 1.33; p=0.014), gender (female) (OR 6.71; 95% CI 1.68 to 46.12; p=0.005) and disease duration (OR 1.06; 95% CI 1.01 to 1.11; p=0.020). Baseline predictors for flare within 2 years were ultrasound grey scale synovitis sum score (OR 1.19; 95% CI 1.02 to 1.44; p=0.020) and number of previous bDMARDs (OR 4.07; 95% CI 1.35 to 24.72; p=0.007). CONCLUSION: The majority of real-world patients with RA tapering bDMARDs flared during tapering, with the majority regaining remission after stepwise dose increase. Demographic and imaging parameters (MR-osteitis/ultrasound greyscale synovitis) were independent predictors of immediate flare and flare overall and may be of importance for clinical decision-making in patients eligible for tapering. |
format | Online Article Text |
id | pubmed-9791469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97914692022-12-27 Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors Terslev, L Ostergaard, Mikkel Georgiadis, Stylianos Brahe, Cecilie Heegaard Ellegaard, Karen Dohn, UM Fana, Viktoria Møller, Torsten Juul, Lars Huynh, Tuan Khai Krabbe, Simon Ornbjerg, L M Glinatsi, Daniel Røgind, Henrik Hansen, Annette Nørregaard, Jesper Jacobsen, Søren Jensen, Dorte V Manilo, Natalia Asmussen, Karsten Boesen, Mikael Rastiemadabadi, Zoreh Morsel-Carlsen, Lone Møller, Jakob Møllenbach Krogh, Niels Steen Hetland, Merete Lund RMD Open Rheumatoid Arthritis OBJECTIVE: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year. bDMARDs were tapered according to a mandatory clinical guideline to two-thirds of standard dose at baseline, half of dose at week 16 and discontinuation at week 32. Prospective assessments for 2 years included clinical evaluation, conventional radiography, ultrasound and MRI for signs of inflammation and bone changes. Flare was defined as DAS28-CRP ≥2.6 with ∆DAS28-CRP ≥1.2 from baseline. Baseline predictors of flare were assessed by logistic regression analyses. RESULTS: Of 142 included patients, 121 (85%) flared during follow-up of which 86% regained remission within 24 weeks after flare. Patients that flared were more often rheumatoid factor positive, had tried more bDMARDs and had higher baseline ultrasound synovitis sum scores than those not flaring. For patients on standard dose, predictors of flare within 16 weeks after reduction to two-thirds of standard dose were baseline MRI-osteitis (OR 1.16; 95% CI 1.03 to 1.33; p=0.014), gender (female) (OR 6.71; 95% CI 1.68 to 46.12; p=0.005) and disease duration (OR 1.06; 95% CI 1.01 to 1.11; p=0.020). Baseline predictors for flare within 2 years were ultrasound grey scale synovitis sum score (OR 1.19; 95% CI 1.02 to 1.44; p=0.020) and number of previous bDMARDs (OR 4.07; 95% CI 1.35 to 24.72; p=0.007). CONCLUSION: The majority of real-world patients with RA tapering bDMARDs flared during tapering, with the majority regaining remission after stepwise dose increase. Demographic and imaging parameters (MR-osteitis/ultrasound greyscale synovitis) were independent predictors of immediate flare and flare overall and may be of importance for clinical decision-making in patients eligible for tapering. BMJ Publishing Group 2022-12-22 /pmc/articles/PMC9791469/ /pubmed/36549857 http://dx.doi.org/10.1136/rmdopen-2022-002796 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Rheumatoid Arthritis Terslev, L Ostergaard, Mikkel Georgiadis, Stylianos Brahe, Cecilie Heegaard Ellegaard, Karen Dohn, UM Fana, Viktoria Møller, Torsten Juul, Lars Huynh, Tuan Khai Krabbe, Simon Ornbjerg, L M Glinatsi, Daniel Røgind, Henrik Hansen, Annette Nørregaard, Jesper Jacobsen, Søren Jensen, Dorte V Manilo, Natalia Asmussen, Karsten Boesen, Mikael Rastiemadabadi, Zoreh Morsel-Carlsen, Lone Møller, Jakob Møllenbach Krogh, Niels Steen Hetland, Merete Lund Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title | Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title_full | Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title_fullStr | Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title_full_unstemmed | Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title_short | Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors |
title_sort | flare during tapering of biological dmards in patients with rheumatoid arthritis in routine care: characteristics and predictors |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791469/ https://www.ncbi.nlm.nih.gov/pubmed/36549857 http://dx.doi.org/10.1136/rmdopen-2022-002796 |
work_keys_str_mv | AT terslevl flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT ostergaardmikkel flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT georgiadisstylianos flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT brahececilieheegaard flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT ellegaardkaren flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT dohnum flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT fanaviktoria flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT møllertorsten flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT juullars flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT huynhtuankhai flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT krabbesimon flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT ornbjerglm flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT glinatsidaniel flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT røgindhenrik flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT hansenannette flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT nørregaardjesper flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT jacobsensøren flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT jensendortev flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT manilonatalia flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT asmussenkarsten flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT boesenmikael flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT rastiemadabadizoreh flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT morselcarlsenlone flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT møllerjakobmøllenbach flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT kroghnielssteen flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors AT hetlandmeretelund flareduringtaperingofbiologicaldmardsinpatientswithrheumatoidarthritisinroutinecarecharacteristicsandpredictors |